These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 29869516)
1. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits. Fouda NH; Abdelrehim RT; Hegazy DA; Habib BA Drug Deliv; 2018 Nov; 25(1):1340-1349. PubMed ID: 29869516 [TBL] [Abstract][Full Text] [Related]
2. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Emad Eldeeb A; Salah S; Ghorab M Drug Deliv; 2019 Dec; 26(1):509-521. PubMed ID: 31090464 [TBL] [Abstract][Full Text] [Related]
3. Effect of Formulation Variables and Gamma Sterilization on Transcorneal Permeation and Stability of Proniosomal Gels as Ocular Platforms for Antiglaucomal Drug. Sayed S; Abdelmoteleb M; Amin MM; Khowessah OM AAPS PharmSciTech; 2020 Feb; 21(3):87. PubMed ID: 32016607 [TBL] [Abstract][Full Text] [Related]
4. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study. Singh J; Chhabra G; Pathak K Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522 [TBL] [Abstract][Full Text] [Related]
5. Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation. Kouchak M; Mahmoodzadeh M; Farrahi F AAPS PharmSciTech; 2019 Jun; 20(5):210. PubMed ID: 31161269 [TBL] [Abstract][Full Text] [Related]
6. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles. Park CG; Kim YK; Kim SN; Lee SH; Huh BK; Park MA; Won H; Park KH; Choy YB Int J Pharm; 2017 Apr; 522(1-2):66-73. PubMed ID: 28216468 [TBL] [Abstract][Full Text] [Related]
7. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation. Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SOA; Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG Int J Pharm; 2019 Oct; 570():118662. PubMed ID: 31491481 [TBL] [Abstract][Full Text] [Related]
8. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride. Hasan AA Pharm Dev Technol; 2014 Sep; 19(6):748-54. PubMed ID: 23964893 [TBL] [Abstract][Full Text] [Related]
9. Quality by design steered approach for co-encapsulation of timolol maleate and dorzolamide hydrochloride in injectable liposomes. Verma P; Rajpurohit R; Yadav KS Int J Pharm; 2024 Oct; 664():124566. PubMed ID: 39154918 [TBL] [Abstract][Full Text] [Related]
10. Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits. Jain N; Verma A; Jain N Drug Deliv; 2020 Dec; 27(1):888-899. PubMed ID: 32551978 [TBL] [Abstract][Full Text] [Related]
11. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits. Afouna MI; Khedr A; Abdel-Naim AB; Al-Marzoqi A J Pharm Sci; 2010 Jan; 99(1):119-27. PubMed ID: 19530071 [TBL] [Abstract][Full Text] [Related]
12. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N; Nakrani H; Raval M; Sheth N Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408 [TBL] [Abstract][Full Text] [Related]
13. Development and optimization of boswellic acid-loaded proniosomal gel. Mehta M; Dureja H; Garg M Drug Deliv; 2016 Oct; 23(8):3072-3081. PubMed ID: 26953869 [TBL] [Abstract][Full Text] [Related]
14. Cubogel as potential platform for glaucoma management. Sayed S; Abdel-Moteleb M; Amin MM; Khowessah OM Drug Deliv; 2021 Dec; 28(1):293-305. PubMed ID: 33509004 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures. Afify EAMR; Elsayed I; Gad MK; Mohamed MI; Afify AEMR PLoS One; 2018; 13(2):e0191415. PubMed ID: 29401498 [TBL] [Abstract][Full Text] [Related]
16. Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma. Fathalla D; Fouad EA; Soliman GM Drug Dev Ind Pharm; 2020 May; 46(5):806-813. PubMed ID: 32281424 [No Abstract] [Full Text] [Related]
17. Enhanced ocular bioavailability of fluconazole from niosomal gels and microemulsions: formulation, optimization, and in vitro-in vivo evaluation. Soliman OAE; Mohamed EA; Khatera NAA Pharm Dev Technol; 2019 Jan; 24(1):48-62. PubMed ID: 29210317 [TBL] [Abstract][Full Text] [Related]
18. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Dubey V; Mohan P; Dangi JS; Kesavan K Int J Biol Macromol; 2020 Jun; 152():1224-1232. PubMed ID: 31751741 [TBL] [Abstract][Full Text] [Related]
19. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613 [TBL] [Abstract][Full Text] [Related]
20. Cubic and hexagonal liquid crystal gels for ocular delivery with enhanced effect of pilocarpine nitrate on anti-glaucoma treatment. Xingqi W; Yong Z; Xing L; Yang W; Jie H; Rongfeng H; Shuangying G; Xiaoqin C Drug Deliv; 2019 Dec; 26(1):952-964. PubMed ID: 31544551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]